Stocks
Mirati Therapeutics, Inc.MRTX
NASDAQHealthcareBiotechnology$58.70-0.17%
Focused on oncology drug development, the company develops targeted cancer therapies aimed at genetically defined tumors, with a particular emphasis on KRAS-driven cancers. Its lead asset, the KRAS G12C inhibitor adagrasib, has been a key driver of investor attention as the firm works through regula...
Market Cap: $4.1B52W Range: $27.30 – $64.41
Congressional Interest in Mirati Therapeutics, Inc. (MRTX)
1 member of Congress has disclosed 2 trades in Mirati Therapeutics, Inc. (MRTX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
1
Buys
1
Sells
1
Who in Congress Is Trading MRTX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-04-10 | Daniel Goldman | sell | $1K – $15K |
| 2023-03-06 | Daniel Goldman | buy | $1K – $15K |